Our site uses cookies. Learn more about our use of cookies: cookie policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to content Skip to footer
Subscribe Now
News

Anivive Lifesciences Completes Pivotal Field Study of Laverdia-CA1 (Verdinexor Tablets) for Canine Lymphoma

Shots:

  • Anivive has reported completion of its pivotal trial of Laverdia-CA1 to treat dogs with lymphoma where, the final study site was closed on Dec 12, 2024
  • The trial assessed Laverdia-CA1 vs PBO in dogs (n=150; selected via AniviveTrial platform from >700 applications) in 12 US sites with results expected in coming months
  • Additionally, Anivive plans to submit the effectiveness technical section for the US FDA review this summer, with all other major NADA sections approved, & will seek complete approval in Brazil, Australia, UK, & EU post data finalization

Ref: Prnewswire | Image: Anivive

Related News:- Anivive Lifesciences Receives $20M Funding from Leonid Capital Partners to Develop Novel Programs for Pets

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Tags:
Share Post

You May Also Like

Axsome
April 2, 2025
Axsome Therapeutics Reports Topline Data of P-III (PARADIGM) Trial of Solriamfetol for Major Depressive Disorder (MDD) regardless of Excessive Daytime Sleepiness (EDS)
Apellis
April 2, 2025
Apellis Pharmaceuticals Reports the US FDA’s sNDA Acceptance & Priority Review of Empaveli for C3 Glomerulopathy and Primary IC-MPGN
GRIN Therapeutic
February 27, 2025
GRIN Therapeutics Reports the US FDA’s Breakthrough Therapy Designation for Radiprodil to Treat Seizures in GRIN-Related Neurodevelopmental Disorder

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]